Dr. Mark J. Alberts, MD
Neurology (Neurology Physician)
- Medicare participating
At a glance
- Medical school
- Tufts University School of Medicine (1982)
- Years since graduation
- 44
- In the NPI registry since
- 2005
- Medicare patients seen, 2024
- 24
Licensed in Illinois since 2001, according to the Illinois Department of Financial and Professional Regulation. We show license dates only for the states that publish them in bulk; see which states do. For other states, check the state medical board.
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 1982Medical school: Tufts University School of Medicine
- 2005Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Neurology Physician primary
TX license P5769 (first issued 2013; canc non-renewal) · IL license 036104399 (first issued 2001; not renewed)
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Hartford Hospital Hartford, CT
- St Vincent's Medical Center Bridgeport, CT
Medical groups
- Hartford Healthcare Medical Group Specialists PLLC (1,588 clinicians)
- Hartford Hospital (1,044 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 24
- Services billed
- 39
- Patients’ average age
- 79
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Donepezil Hcl Other prescribers in Dallas, TX | 43 |
| Memantine Hcl Er (memantine hcl) Other prescribers in Dallas, TX | 32 |
| Gabapentin Other prescribers in Dallas, TX | 21 |
| Eliquis (apixaban) Other prescribers in Dallas, TX | 15 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 7 companies reported 14 payments worth $6,010 in total to this clinician.
| Novartis Pharmaceuticals Corporation | $2,888 |
|---|---|
| AstraZeneca Pharmaceuticals LP | $2,601 |
| Lilly USA, LLC | $238 |
| DePuy Synthes Sales Inc. | $136 |
| Axsome Therapeutics, Inc. | $113 |
| Pfizer Inc. | $19.15 |
| Eisai Inc. | $15.10 |
| Consulting Fee | $2,888 |
|---|---|
| Compensation for services other than consulting (speaking, faculty) | $2,500 |
| Food and Beverage | $622 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Novartis Pharmaceuticals Corporation Aug 27, 2025 | Consulting Fee | $2,888 |
| AstraZeneca Pharmaceuticals LP Feb 16, 2025 | Compensation for services other than consulting (speaking, faculty) ANDEXXA · Rare Disease Company’s descriptionSpeaker Fee | $2,500 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 1 industry-funded study in 2025, from 1 company. The companies reported $10,125 in research payments for these studies, mostly to the institutions running them.
- A multinational observational longitudinal study to describe the patient characteristics, health care interventions, and health outcomes of patients with major bleedings in the context of Factor Xa inhibitor treatment
AstraZeneca Pharmaceuticals LP
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.